SELLAS Life Sciences Group

122 articles about SELLAS Life Sciences Group

• SELLAS Life Sciences Announces Positive Recommendation from REGAL Independent Data Monitoring Committee of Galinpepimut-S in Acute Myeloid Leukemia

  12/4/2023

  SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”) today announced a positive review of the ongoing Phase 3 REGAL clinical trial of galinpepimut-S (GPS) in acute myeloid leukemia (AML) by the Independent Data Monitoring Committee (IDMC).

• SELLAS Life Sciences Reaches Target Enrollment ex-China in Phase 3 REGAL Trial of Galinpepimut-S in Acute Myeloid Leukemia

  11/29/2023

  SELLAS Life Sciences Group, Inc. today announced that the target patient enrollment outside of mainland China in the ongoing Phase 3 REGAL trial of galinpepimut-S (GPS) in patients with acute myeloid leukemia (AML).

• SELLAS Life Sciences Receives Favorable FDA Type C Meeting Feedback on Chemistry, Manufacturing, and Controls (CMC) Biologics License Application (BLA) Filing Strategy for Galinpepimut-S (GPS)

  11/13/2023

  SELLAS Life Sciences Group, Inc. today announced that it recently concluded a Type C meeting with the U.S. Food and Drug Administration (FDA) regarding the Company’s Chemistry, Manufacturing, and Controls (CMC) sections in a potential biologics license application (“BLA”) for SELLAS’ lead product candidate, galinpepimut-S (GPS).

• SELLAS Provides Business Update and Reports Third Quarter 2023 Financial Results

  11/9/2023

  SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today provided a business update and reported its financial results for the quarter ended September 30, 2023.

• SELLAS Life Sciences Presents Positive Key Immunobiological and Clinical Data from Phase 1/2 Trial of Galinpepimut-S (GPS) in Combination with Keytruda® in WT1+ Platinum-Resistant Advanced Ovarian Cancer at the IGCS 2023 Annual Global Meeting

  11/6/2023

  SELLAS Life Sciences Group, Inc. announced final clinical and immunobiological data from the Phase 1/2 clinical trial of galinpepimut-S in combination with pembrolizumab in Wilms’ tumor-1 -positive platinum-resistant ovarian cancer.

• SELLAS Life Sciences Announces $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

  10/31/2023

  SELLAS Life Sciences Group, Inc. announced that it has entered into a securities purchase agreement with a single, healthcare-focused U.S. institutional investor for the purchase and sale of 3,652,300 shares of common stock at a purchase price of $1.0952 per share, priced at-the-market under Nasdaq rules pursuant to a registered direct offering resulting in total gross proceeds of approximately $4 million.

• SELLAS Life Sciences to Present Final Data from Phase 1/2 Study of Galinpepimut-S in Combination with Keytruda® (pembrolizumab) in Patients with WT1+ Platinum-Resistant Advanced Ovarian Cancer at the IGCS 2023 Annual Global Meeting

  10/17/2023

  SELLAS Life Sciences Group, Inc. announced that the topline clinical data from the final analysis of the Phase 1/2 clinical trial of galinpepimut-S in combination with pembrolizumab in Wilms’ tumor-1 -positive platinum-resistant ovarian cancer will be presented at an e-Poster session at the 2023 International Gynecologic Cancer Society Annual Global Meeting taking place November 5-7, 2023, in Seoul, South Korea.

• SELLAS Announces Positive Initial Topline Phase 2a Data of SLS009 in Acute Myeloid Leukemia

  10/16/2023

  SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the “Company”) today announced positive initial topline data at the 45 mg (safety) dose level from its ongoing Phase 2a clinical trial of its novel and highly selective CDK9 inhibitor, SLS009, in combination with venetoclax and azacitidine (aza/ven) in patients with relapsed/refractory (r/r) acute myeloid leukemia (AML) who did not respond or stopped responding to venetoclax-based therapies.

• SELLAS Announces First Patient Dosed in Phase Ib/II Trial of SLS009 (GFH009) in Relapsed/Refractory Peripheral T-cell Lymphomas

  10/11/2023

  SELLAS Life Sciences Group, Inc. today announced that its partner GenFleet Therapeutics (Shanghai), Inc. has dosed the first patient in a Phase Ib/II trial evaluating SLS009 (GFH009) in relapsed/refractory Peripheral T-cell Lymphomas (PTCL).

• SELLAS Announces Positive Topline Data in Lymphoma Cohort from SLS009 Phase 1 Dose-Escalation Trial, Supporting Advancement to Phase 2 Clinical Study; Primary and Secondary Endpoints Met

  9/21/2023

  SELLAS Life Sciences Group, Inc. today announced positive topline data for the patient group with relapsed/refractory (r/r) lymphomas from the Phase 1 dose-escalation trial of its CDK9 inhibitor, SLS009 (GFH009).

• SELLAS Life Sciences to Participate in the Cantor Fitzgerald Global Healthcare Conference

  9/18/2023

  SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the “Company”) today announced that Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS, and members of the SELLAS management team will participate in a panel presentation and one-on-one investor meetings at the Cantor Fitzgerald Global Healthcare Conference, taking place in New York, NY, from September 26-28, 2023.

• SELLAS Life Sciences Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue Without any Modifications

  8/22/2023

  SELLAS Life Sciences Group, Inc. today announced a positive review of the ongoing Phase 3 REGAL clinical trial of galinpepimut-S (GPS) in acute myeloid leukemia (AML) by the Independent Data Monitoring Committee (IDMC).

• SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2023 Financial Results

  8/10/2023

  SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today provided a business update and reported its financial results for the quarter ended June 30, 2023.

• SELLAS Life Sciences Reports Positive Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma

  6/28/2023

  SELLAS Life Sciences Group, Inc. today announced topline clinical data from a Phase 1 investigator-sponsored clinical trial of its lead clinical candidate, galinpepimut-S (GPS).

• SELLAS Announces First Patient Dosed in Phase 2a Clinical Trial of GFH009 in Acute Myeloid Leukemia

  6/22/2023

  SELLAS Life Sciences Group, Inc. today announced that the first patient has been dosed in a Phase 2a study of its novel and highly selective CDK9 inhibitor, GFH009, in combination with venetoclax and azacitidine (aza/ven) in patients with relapsed/refractory (r/r) acute myeloid leukemia (AML) who did not respond or stopped responding to venetoclax-based therapies.

• SELLAS Life Sciences Announces Abstract Accepted for Presentation at International Gynecologic Cancer Society Annual Meeting

  6/15/2023

  SELLAS Life Sciences Group, Inc. announced acceptance of an abstract for a poster presentation at the Annual Global Meeting of the International Gynecologic Cancer Society which will be held November 5-7, 2023, in Seoul, South Korea.

• SELLAS to Participate in Maxim Group Healthcare Virtual Conference

  6/13/2023

  SELLAS Life Sciences Group, Inc. announced that Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS, has been invited to participate in a fireside chat at the Maxim Group Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest, taking place June 20-22, 2023.

• SELLAS Life Sciences to Present Phase 3 REGAL Trial in Progress Poster at 2023 ASCO Annual Meeting

  5/25/2023

  SELLAS Life Sciences Group, Inc. announced that a trial in progress poster for the Phase 3 REGAL study of galinpepimut-S in acute myeloid leukemia will be presented at the American Society of Clinical Oncology Annual Meeting, taking place June 2-6, 2023 in Chicago.

• SELLAS Life Sciences to Host Virtual Expert Panel Discussion on GFH009 in Acute Myeloid Leukemia

  5/16/2023

  SELLAS Life Sciences Group, Inc. today announced it will host a virtual panel discussion on Tuesday, May 30, 2023 at 8:00 a.m. EST.

• SELLAS Announces Positive Topline Data from GFH009 Phase 1 Dose-Escalation Trial in Acute Myeloid Leukemia Cohort Supporting Advancement to Phase 2 Clinical Study

  5/4/2023

  SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced positive topline data for the cohort of patients with acute myeloid leukemia (AML) from its Phase 1 dose-escalation trial in relapsed/refractory (r/r) myeloid malignancies for GFH009, its CDK9 inhibitor.